Share on StockTwits
 

Analysts’ ratings reiterations for Monday, January 13th:

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its market perform rating reissued by analysts at JMP Securities. The analysts wrote, “Development of ALNY RNAi therapeutic candidates is progressing ahead of prior guidance; reiterate Market Outperform rating and $68 price target on Alnylam. Last Friday, ALNY announced key pipeline goals for 2014, including that the company now expects to exceed its original “Alnylam 5×15″ guidance from 2011. Previously, Alnylam had guided to have five genetic medicine programs in the clinic by the end of 2015, but now expects to end 2015 with six to seven genetic medicine programs in the clinic, including at least two programs in Phase III and five to six programs that will have achieved human proof-of-concept results supporting further development. We reiterate our Market Outperform rating and $68 PT based on DCF and SOTP valuation methodologies.”

Barclays PLC (LON:BARC) had its buy rating reissued by analysts at Investec. The firm currently has a GBX 305 ($5.03) price target on the stock.

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its market perform rating reissued by analysts at JMP Securities. The analysts wrote, “BCRX provided an update on data flow from its HAE program, including data presentations on kallikrein inhibitor, BCX4161, at AAAAI in late February/early March and data from the 28-day proof-of-concept study in 1H14, which we view as a key value driver for the company. BioCryst has also profiled its second generation kallikrein inhibitors, which have the expected benefits of better bio-availability (at least 5x BCX4161) and selectivity (at least 4x more selective against tissue factor VII). We anticipate that one of these compounds will move into human development in 1H15. BioCryst is also planning to leverage its drug discovery efforts into a second orphan disease in 2H14. We recommend shares of BioCryst into potentially transformative Phase 2a data.”

Bodycote (LON:BOY) had its outperform rating reissued by analysts at Credit Suisse. Credit Suisse currently has a GBX 760 ($12.52) target price on the stock.

Burberry Group (LON:BRBY) had its hold rating reiterated by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 1,500 ($24.72) price target on the stock.

Capita Plc (LON:CPI) had its outperform rating reissued by analysts at Credit Suisse. They currently have a GBX 1,150 ($18.95) target price on the stock.

Egdon Resources Plc (LON:EDR) had its buy rating reiterated by analysts at Cantor Fitzgerald Europe. Cantor Fitzgerald Europe currently has a GBX 17 ($0.28) target price on the stock.

GKN (LON:GKN) had its outperform rating reiterated by analysts at Credit Suisse. The firm currently has a GBX 430 ($7.09) price target on the stock.

Green Mountain Coffee Roasters (NASDAQ:GMCR) had its buy rating reissued by analysts at KeyCorp.

Hammerson (LON:HMSO) had its buy rating reaffirmed by analysts at Galvan Research. Galvan Research currently has a GBX 540 ($8.90) target price on the stock.

IMI (LON:IMI) had its outperform rating reissued by analysts at Credit Suisse. Credit Suisse currently has a GBX 1,640 ($27.03) target price on the stock.

WM Morrison Supermarkets (LON:MRW) had its buy rating reiterated by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 330 ($5.44) target price on the stock.

Rotork (LON:ROR) had its outperform rating reaffirmed by analysts at Credit Suisse. The firm currently has a GBX 3,230 ($53.23) target price on the stock.

Sports Direct International (LON:SPD) had its hold rating reiterated by analysts at Cantor Fitzgerald Europe. They currently have a GBX 680 ($11.21) price target on the stock.

Weir Group (LON:WEIR) had its neutral rating reaffirmed by analysts at Credit Suisse. They currently have a GBX 2,210 ($36.42) target price on the stock.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.